Patents by Inventor Nupam P. Mahajan
Nupam P. Mahajan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200018762Abstract: Phosphorylation of histones was observed at certain tyrosine residues which have not been associated with epigenetic modification. These sites include H2B Tyr37, H4 Tyr88 and Tyr51 and H3 Tyr99. Kinases responsible for the phosphorylation as well as downstream genes regulated by such phosphorylation were also identified. Antibodies that are specific to such phosphorylated histones have been generated, which are useful for detecting the phosphorylation and related events. With such findings, the present disclosure provides compositions and methods for disease diagnosis, prognosis and therapy selection, in particular for cancer, obesity and diabetes.Type: ApplicationFiled: April 17, 2019Publication date: January 16, 2020Inventors: Kiran Mahajan, Nupam P. Mahajan
-
Publication number: 20190212343Abstract: Methods for disease diagnosis, prognosis and therapy selection. Compositions for use in these methods and selected therapies for treatment are also disclosed.Type: ApplicationFiled: September 24, 2018Publication date: July 11, 2019Inventor: Nupam P. Mahajan
-
Patent number: 10336734Abstract: Described are cancer therapies and anti-cancer compounds. In particular, disclosed are inhibitors of ACK1 tyrosine kinase and their use in the treatment of cancer. Methods of screening for new ACK1 tyrosine kinase inhibitors are also disclosed. In specific example, compound having Formula I are disclosed.Type: GrantFiled: August 2, 2016Date of Patent: July 2, 2019Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.Inventors: Nupam P. Mahajan, Kiran N. Mahajan, Nicholas J. Lawrence, Harshani R. Lawrence
-
Publication number: 20180215738Abstract: Described are cancer therapies and anti-cancer compounds. In particular, disclosed are inhibitors of ACK1 tyrosine kinase and their use in the treatment of cancer. Methods of screening for new ACK1 tyrosine kinase inhibitors are also disclosed. In specific example, compound having Formula I are disclosed.Type: ApplicationFiled: August 2, 2016Publication date: August 2, 2018Inventors: Nupam P. Mahajan, Kiran N. Mahajan, Nicholas J. Lawrence, Harshani R. Lawrence
-
Patent number: 10017478Abstract: Described are cancer therapies and anti-cancer compounds. In particular, disclosed are inhibitors of Ack1 tyrosine kinase and their use in the treatment of cancer. Methods of screening for new Ack1 tyrosine kinase inhibitors are also disclosed. In specific example, compound having Formula I through IV are disclosed.Type: GrantFiled: November 9, 2017Date of Patent: July 10, 2018Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.Inventors: Nupam P. Mahajan, Kiran N. Mahajan, Nicholas J. Lawrence, Harshani R. Lawrence
-
Publication number: 20180155297Abstract: Described are cancer therapies and anti-cancer compounds. In particular, disclosed are inhibitors of Ack1 tyrosine kinase and their use in the treatment of cancer. Methods of screening for new Ack1 tyrosine kinase inhibitors are also disclosed. In specific example, compound having Formula I through IV are disclosed.Type: ApplicationFiled: November 9, 2017Publication date: June 7, 2018Inventors: Nupam P. Mahajan, Kiran N. Mahajan, Nicholas J. Lawrence, Harshani R. Lawrence
-
Patent number: 9850216Abstract: Described are cancer therapies and anti-cancer compounds. In particular, disclosed are inhibitors of Ack1 tyrosine kinase and their use in the treatment of cancer. Methods of screening for new Ack1 tyrosine kinase inhibitors are also disclosed. In specific example, compound having Formula I through IV are disclosed.Type: GrantFiled: August 6, 2014Date of Patent: December 26, 2017Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.Inventors: Nupam P. Mahajan, Kiran N. Mahajan, Nicholas J. Lawrence, Harshani R. Lawrence
-
Publication number: 20170299599Abstract: Phosphorylation of histones was observed at certain tyrosine residues which have not been associated with epigenetic modification. These sites include H2B Tyr37, H4 Tyr88 and Tyr 51 and H3 Tyr99. Kinases responsible for the phosphorylation as well as downstream genes regulated by such phosphorylation were also identified. Antibodies that are specific to such phosphorylated histones have been generated, which are useful for detecting the phosphorylation and related events. With such findings, the present disclosure provides compositions and methods for disease diagnosis, prognosis and therapy selection, in particular for cancer, obesity and diabetes.Type: ApplicationFiled: March 13, 2017Publication date: October 19, 2017Inventors: Kiran Mahajan, Nupam P. Mahajan
-
Patent number: 9594084Abstract: Phosphorylation of histones was observed at certain tyrosine residues which have not been associated with epigenetic modification. These sites include H2B Tyr37, H4 Tyr88 and Tyr 51 and H3 Tyr99. Kinases responsible for the phosphorylation as well as downstream genes regulated by such phosphorylation were also identified. Antibodies that are specific to such phosphorylated histones have been generated, which are useful for detecting the phosphorylation and related events. With such findings, the present disclosure provides compositions and methods for disease diagnosis, prognosis and therapy selection, in particular for cancer, obesity and diabetes.Type: GrantFiled: July 2, 2014Date of Patent: March 14, 2017Assignee: H. Lee Moffitt Cancer Center and Research InstituteInventors: Kiran Mahajan, Nupam P. Mahajan
-
Publication number: 20160176826Abstract: Described are cancer therapies and anti-cancer compounds. In particular, disclosed are inhibitors of Ack1 tyrosine kinase and their use in the treatment of cancer. Methods of screening for new Ack1 tyrosine kinase inhibitors are also disclosed. In specific example, compound having Formula I through IV are disclosed.Type: ApplicationFiled: August 6, 2014Publication date: June 23, 2016Inventors: Nupam P. Mahajan, Kiran N. Mahajan, Nicholas J. Lawrence, Harshani R. Lawrence
-
Publication number: 20160091498Abstract: Methods for disease diagnosis, prognosis and therapy selection. Compositions for use in these methods and selected therapies for treatment are also disclosed.Type: ApplicationFiled: September 21, 2015Publication date: March 31, 2016Inventor: Nupam P. Mahajan
-
Publication number: 20150011567Abstract: Phosphorylation of histones was observed at certain tyrosine residues which have not been associated with epigenetic modification. These sites include H2B Tyr37, H4 Tyr88 and Tyr 51 and H3 Tyr99. Kinases responsible for the phosphorylation as well as downstream genes regulated by such phosphorylation were also identified. Antibodies that are specific to such phosphorylated histones have been generated, which are useful for detecting the phosphorylation and related events. With such findings, the present disclosure provides compositions and methods for disease diagnosis, prognosis and therapy selection, in particular for cancer, obesity and diabetes.Type: ApplicationFiled: July 2, 2014Publication date: January 8, 2015Inventors: Kiran Mahajan, Nupam P. Mahajan
-
Publication number: 20140134178Abstract: Phosphorylation of histones was observed at certain tyrosine residues which have not been associated with epigenetic modification. These sites include H2B Tyr37, H4 Tyr88 and Tyr51 and H3 Tyr99. Kinases responsible for the phosphorylation as well as downstream genes regulated by such phosphorylation were also identified. Antibodies that are specific to such phosphorylated histones have been generated, which are useful for detecting the phosphorylation and related events. With such findings, the present disclosure provides compositions and methods for disease diagnosis, prognosis and therapy selection, in particular for cancer, obesity and diabetes.Type: ApplicationFiled: January 4, 2013Publication date: May 15, 2014Applicant: H. LEE MOFFIT CANCER CENTER AND RESEARCH INSTITUTEInventors: Kiran Mahajan, Nupam P. Mahajan
-
Publication number: 20140045883Abstract: Compositions and methods are disclosed for treating Triple Negative Breast Cancers (TNBCs). The methods involve administering to a subject with TNBC a composition containing an Ack1 kinase inhibitor. In some embodiments, the method involves first assaying a sample from the subject for Tyr176-phosphorylated-AKT and/or Tyr284-phosphorylated-Ack1. In these embodiments, detection of the phosphorylated AKT and/or Ack1 is an indication that the subject is a suitable candidate for treatment with the Ack1 kinase inhibitor.Type: ApplicationFiled: August 12, 2013Publication date: February 13, 2014Applicant: H. Lee Moffitt Cancer Center and Research Institute, Inc.Inventors: Nupam P. Mahajan, Kiran N. Mahajan
-
Patent number: 8557516Abstract: AKT/PKB kinase is a key signaling component of one of the most frequently activated pathways in cancer and is a major target of cancer drug development. The present study uncovered that growth factors binding to RTKs lead to activation of a non-receptor tyrosine kinase, Ack1 (TNK2), which directly phosphorylates AKT at a conserved tyrosine 176 residue. Tyr176-phosphorylated AKT binds to phosphatidic acid and localizes to the plasma membrane, leading to AKT activation. Expression levels of Tyr176-phosphorylated-AKT and Tyr284-phosphorylated-Ack1 were positively correlated with the severity of disease progression, and inversely correlated with the survival of breast, prostate, lung and pancreatic cancer patients.Type: GrantFiled: August 8, 2011Date of Patent: October 15, 2013Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.Inventors: Nupam P. Mahajan, Kiran N. Mahajan
-
Publication number: 20120053225Abstract: AKT/PKB kinase is a key signaling component of one of the most frequently activated pathways in cancer and is a major target of cancer drug development. The present study uncovered that growth factors binding to RTKs lead to activation of a non-receptor tyrosine kinase, Ack1 (TNK2), which directly phosphorylates AKT at a conserved tyrosine 176 residue. Tyr176-phosphorylated AKT binds to phosphatidic acid and localizes to the plasma membrane, leading to AKT activation. Expression levels of Tyr176-phosphorylated-AKT and Tyr284-phosphorylated-Ack1 were positively correlated with the severity of disease progression, and inversely correlated with the survival of breast, prostate, lung and pancreatic cancer patients.Type: ApplicationFiled: August 8, 2011Publication date: March 1, 2012Applicant: H. Lee Moffitt Cancer Center and Research Institute, Inc.Inventors: Nupam P. Mahajan, Kiran N. Mahajan